HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Anirban Maitra Selected Research

Adenocarcinoma

1/2022Stromal HIF2 Regulates Immune Suppression in the Pancreatic Cancer Microenvironment.
1/2022Loss of Rnf43 Accelerates Kras-Mediated Neoplasia and Remodels the Tumor Immune Microenvironment in Pancreatic Adenocarcinoma.
1/2022CES2 sustains HNF4α expression to promote pancreatic adenocarcinoma progression through an epoxide hydrolase-dependent regulatory loop.
1/2022Innate immune mediator, Interleukin-1 receptor accessory protein (IL1RAP), is expressed and pro-tumorigenic in pancreatic cancer.
1/2022Mass Transport Model of Radiation Response: Calibration and Application to Chemoradiation for Pancreatic Cancer.
1/2022Translational advances in pancreatic ductal adenocarcinoma therapy.
1/2022Fungal mycobiome drives IL-33 secretion and type 2 immunity in pancreatic cancer.
1/2022Membrane-bound MMP-14 protease-activatable adeno-associated viral vectors for gene delivery to pancreatic tumors.
11/2021Elucidation of Tumor-Stromal Heterogeneity and the Ligand-Receptor Interactome by Single-Cell Transcriptomics in Real-world Pancreatic Cancer Biopsies.
10/2021GRP78 expression and prognostic significance in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant therapy versus surgery first.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Anirban Maitra Research Topics

Disease

266Neoplasms (Cancer)
11/2022 - 06/2002
184Pancreatic Neoplasms (Pancreatic Cancer)
04/2022 - 04/2002
120Adenocarcinoma
01/2022 - 07/2002
32Neoplasm Metastasis (Metastasis)
03/2022 - 07/2003
24Carcinogenesis
01/2022 - 01/2003
19Carcinoma (Carcinomatosis)
01/2020 - 06/2002
11Neoplasms, Cystic, Mucinous, and Serous
01/2022 - 05/2005
9Hypoxia (Hypoxemia)
01/2022 - 03/2007
8Cholangiocarcinoma
12/2013 - 03/2004
7Melanoma (Melanoma, Malignant)
11/2019 - 02/2002
7Breast Neoplasms (Breast Cancer)
11/2019 - 08/2002
7Barrett Esophagus (Barrett's Esophagus)
02/2014 - 03/2005
6Hepatocellular Carcinoma (Hepatoma)
03/2022 - 08/2002
6Inflammation (Inflammations)
03/2016 - 12/2004
5Disease Progression
11/2022 - 01/2019
5Metaplasia
09/2021 - 02/2006
5Chronic Pancreatitis
01/2018 - 11/2002
4Fibrosis (Cirrhosis)
01/2021 - 04/2006
4Circulating Neoplastic Cells
11/2019 - 09/2012
4Pancreatic Cyst
03/2014 - 01/2011
4Adenoma (Adenomas)
01/2006 - 09/2002
3Genomic Instability
01/2021 - 01/2009
3Renal Cell Carcinoma (Grawitz Tumor)
11/2019 - 12/2011
3Cysts
12/2016 - 12/2011

Drug/Important Bio-Agent (IBA)

73Proteins (Proteins, Gene)FDA Link
01/2022 - 07/2002
49Biomarkers (Surrogate Marker)IBA
06/2021 - 01/2003
31GemcitabineFDA Link
01/2020 - 09/2006
28DNA (Deoxyribonucleic Acid)IBA
01/2022 - 07/2003
19Pharmaceutical PreparationsIBA
01/2022 - 03/2005
18MicroRNAs (MicroRNA)IBA
01/2021 - 06/2007
18AntigensIBA
10/2020 - 01/2003
16RNA (Ribonucleic Acid)IBA
11/2022 - 01/2003
16Messenger RNA (mRNA)IBA
11/2022 - 09/2003
14Transcription Factors (Transcription Factor)IBA
01/2021 - 01/2003
13LigandsIBA
11/2021 - 10/2003
13Phosphotransferases (Kinase)IBA
01/2021 - 11/2004
12EnzymesIBA
01/2021 - 01/2003
10AntibodiesIBA
01/2022 - 09/2002
10ErbB Receptors (EGF Receptor)IBA
01/2018 - 06/2003
10CurcuminIBA
12/2015 - 04/2007
10Mitochondrial DNA (mtDNA)IBA
10/2008 - 05/2004
9CytokinesIBA
01/2022 - 01/2006
9MesothelinIBA
12/2008 - 07/2003
8Biological ProductsIBA
01/2022 - 09/2004
8Tumor Biomarkers (Tumor Markers)IBA
11/2008 - 04/2002
7Complementary DNA (cDNA)IBA
01/2014 - 04/2002
6Lactic Acid (Lactate)FDA LinkGeneric
12/2020 - 02/2010
6130-nm albumin-bound paclitaxelIBA
01/2020 - 12/2011
6ChromatinIBA
01/2020 - 01/2009
6Antineoplastic Agents (Antineoplastics)IBA
01/2019 - 07/2006
6Erlotinib Hydrochloride (CP 358,774)FDA Link
01/2018 - 04/2005
6Small Interfering RNA (siRNA)IBA
01/2018 - 04/2005
6cyclopamineIBA
12/2010 - 03/2007
5ProteomeIBA
05/2020 - 09/2004
5Glucose (Dextrose)FDA LinkGeneric
01/2017 - 02/2010
5Cadherins (E-Cadherin)IBA
01/2016 - 03/2007
5Claudin-4IBA
03/2008 - 07/2003
5OligonucleotidesIBA
10/2007 - 12/2003
5fascinIBA
02/2006 - 07/2002
4Immune Checkpoint InhibitorsIBA
01/2022 - 01/2017
4VaccinesIBA
01/2022 - 01/2003
4Irinotecan (Camptosar)FDA LinkGeneric
01/2022 - 12/2012
4CateninsIBA
01/2021 - 03/2015
4Cyclin-Dependent Kinases (cdk Proteins)IBA
11/2020 - 06/2010
4Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
01/2020 - 01/2014
4Mitogen-Activated Protein KinasesIBA
01/2018 - 07/2006
4Therapeutic UsesIBA
01/2016 - 07/2012
4Histones (Histone)IBA
01/2016 - 06/2006
4PolyphenolsIBA
12/2015 - 04/2007
4Amyloid Precursor Protein Secretases (beta-Secretase)IBA
08/2014 - 04/2009
4Histone Deacetylase InhibitorsIBA
05/2014 - 07/2003
4MucinsIBA
03/2014 - 07/2004
4AntimetabolitesIBA
12/2012 - 11/2005
4Type II DNA Topoisomerases (Topoisomerase II)IBA
07/2012 - 09/2003
4Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
05/2010 - 07/2003
4Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
01/2006 - 01/2003
3Indicators and Reagents (Reagents)IBA
04/2022 - 03/2005
3Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA
01/2022 - 01/2011
3ProdrugsIBA
01/2022 - 03/2008
3Glutamine (L-Glutamine)FDA Link
12/2020 - 08/2012
3folfirinoxIBA
11/2020 - 08/2015
3dinaciclibIBA
11/2020 - 10/2011
3Peptides (Polypeptides)IBA
10/2020 - 03/2008
3Pyruvic Acid (Pyruvate)IBA
05/2020 - 08/2015
3Transforming Growth Factor beta (TGF-beta)IBA
11/2019 - 09/2002
3Lactate Dehydrogenase 5IBA
01/2019 - 02/2010
3Protein Isoforms (Isoforms)IBA
01/2017 - 03/2007

Therapy/Procedure

94Therapeutics
01/2022 - 06/2003
17Drug Therapy (Chemotherapy)
01/2022 - 03/2005
10Immunotherapy
01/2022 - 06/2014
10Neoadjuvant Therapy
01/2022 - 10/2015
8Pancreaticoduodenectomy
08/2017 - 01/2006
6Radiotherapy
03/2022 - 03/2007
4Precision Medicine
11/2021 - 03/2013
4Pancreatectomy
11/2017 - 11/2002
4Chemoprevention
01/2014 - 04/2004
4Quantum Dots (Quantum Dot)
10/2012 - 06/2007
3Adjuvant Chemotherapy
10/2019 - 01/2016
3Contraindications
10/2019 - 01/2016
3Lasers (Laser)
11/2017 - 02/2002